Pavel Pavlov

Pavel Pavlov is a Researcher affiliated with the Department of Neurobiology, Care Sciences and Society at Karolinska Institutet (KI), working within the Division of Neurogeriatrics under Bengt Winblad's research group. His primary affiliation is with the Department of Neurobiology, Care Sciences and Society, where he serves as a supervisor for research projects focused on molecular mechanisms of neurodegenerative diseases.

Dr. Pavlov's research program centers on the molecular chaperone network and its role in neurodegenerative disorders, particularly Alzheimer's disease. His work investigates how molecular chaperones—critical for maintaining intracellular protein homeostasis—can be targeted for therapeutic intervention. Rather than pursuing general inhibition or activation of chaperone function (which could be detrimental for long-term therapy), his research focuses on regulating specific cellular processes by inhibiting protein-protein interactions between molecular chaperones and their co-chaperones. This targeted approach aims to develop novel modulators of the molecular chaperone network with therapeutic potential for Alzheimer's disease.

His publication record over the past 16 years demonstrates a consistent and deepening exploration of chaperone-co-chaperone interactions, mitochondrial dysfunction in neurodegeneration, and the development of small molecule therapeutics. The research spans from fundamental molecular mechanisms to preclinical testing in animal models, with several publications describing the development and assessment of lead compounds like GMP-1 that protect mitochondrial function. His work bridges biochemistry, neuroscience, and pharmacology to address the complex protein misfolding pathology characteristic of Alzheimer's and related neurodegenerative diseases.

Dr. Pavlov collaborates extensively within Bengt Winblad's research group and with other researchers at Karolinska Institutet, as evidenced by his numerous co-authored publications. His laboratory work involves sophisticated techniques including x-ray crystallography, computational modeling, biochemical characterization of protein interactions, and testing in fly and mouse models of Alzheimer's disease. The research program has evolved from basic investigations of amyloid-beta import into mitochondria to the development of targeted therapeutic approaches for modulating specific aspects of the molecular chaperone network.